Abstract 2054
Background
Oncology patients with advanced disease frequently undergo Radiation to relieve symptoms such as pain and dyspnoea. These patients have been treated by different health professionals in multiple, complexed and long-term treatments. The goal of this study was to investigate the possibility to help and improve the quality of life of these patients.
Trial design
In the present study, 32 patients participated and were evaluated prospectively. The main criteria for their participation were the following: oncology patients >18 years old with a satisfactory level of verbal communication and advance cancer receiving radiotherapy. EORTC questionnaires (QLQ-C30) and questionnaire for problems and needs for palliative care PNCP-Center for the Quality of Care of the WOK research were used.The quality of life of these patients was assessed prior the beginning of the treatment and that was taken as a quality of life baseline level as well as at the end of their treatment. The present study was conducted from June 2018 to December 2018 in the Radiotherapy Department of "Hygeia" Hospital in Greece. Of the 32 patients who were evaluated 11 were women and 21 were men. Their average age was 65 years old. Also 84,4% of these patients had external help (family, caretaker). A significant improvement in the quality of life was observed only in patients who had home help for 4 hours daily (p.value 0,006).Men seemed to improve the quality of life after treatment (p.value 0,005).The patients reported their palliative care needs in the following rating scale: financial and phychological issues, autonomy, daily activities, spiritual issues, organic symptoms and need for information ,all of which will be presented in detail. Those who have difficulty completing tasks need or depent on others and ask for professional help (p.value 0,001)Radiation therapy alleviates the organic symptoms of patients with advanced disease, but it does not cover their needs that have become more important to them than their organic symptoms. Care for these patients needs a more specialized approach which incorporates the principles of palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract